The behavioral symptoms like hyperkinesia (increased locomotor activity) and the increase in anxiety levels persistent in early stage HD were decreased by blocking A2AR using two A2AR antagonists (SCH 58261 and caffeine; Popoli et al., 2002; Scattoni et al., 2007; Mishra and Kumar, 2014). This evidence concerns the gene ADORA2A and Huntington disease.